NCT02644057 - Dobutamaine Versus Milrinone in Cardiorenal Syndrome | Biotech Hunter

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Cardiorenal Syndrome

Interventions

DRUG

Milrinone

Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight

DRUG

Dobutamine

Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn